Inherited retinal diseases: Progress being made with treatment modalities

Article

The delivery of lipid nanoparticle-based mRNA to the retina is encouraging, according to researchers.

Inherited retinal diseases: Progress being made with treatment modalities

Progress is being made in the treatment modalities for inherited retinal diseases. Specifically, the delivery of lipid nanoparticle (LNP)-based mRNA seems promising to treat these diseases, according to Marco Herrera-Barrera, MD, from the Department of Pharmaceutical Sciences, College of Pharmacy, Robertson Life Sciences Building, Oregon State University, Portland, USA.

Until now, LNP-mediated mRNA delivery could only be achieved to the retinal pigment epithelium (RPE) and Müller glia. “LNPs must overcome ocular barriers to transfect neuronal cells critical for visual phototransduction, the photoreceptors,” the investigators explained.1

They hypothesised that chemically decorating LNPs with a short 7-nucleotide oligomer peptide would facilitate penetration into the neural retina. Previous studies have shown that by crossing biologic barriers, peptides enhanced drug delivery, imaging agents and nanoparticle drug targeting.2,3

In this study, they used a peptide library to identify peptide sequences that bind the neural retina in vivo. Decoration of the peptides on the surface of LNPs with varying surface densities resulted in successful delivery of mRNA to the neural retina in a mouse model, they reported.

“These results translated to the more clinically relevant nonhuman primate, where robust protein expression was observed in the photoreceptors, Müller glia, and RPE. Overall, we identified peptide-conjugated LNPs that can facilitate the delivery of mRNA to the neural retina, expanding the utility of LNP-mRNA therapies for inherited blindness,” they concluded.

References
  1. Herrera-Barrera M, Ryals RC, Gautam M, et al. Peptide-guided lipid nanoparticles deliver mRNA to the neural retina of rodents and nonhuman primates. Sci Adv. 2023;9; doi: 10.1126/sciadv.add4623
  2. Albertini B, Mathieu V, Iraci N, et al. Tumor targeting by peptide-decorated gold nanoparticles. Mol Pharm. 2019;16:2430–2444.
  3. Hennrich U, Kopka K. Lutathera: The first FDA- and EMA-approved radiopharmaceutical for peptide receptor radionuclide therapy. Pharmaceuticals. 2019;12:114.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
Related Content
© 2025 MJH Life Sciences

All rights reserved.